|Bid||47.00 x 900|
|Ask||48.00 x 800|
|Day's Range||47.01 - 47.59|
|52 Week Range||35.10 - 48.11|
|Beta (3Y Monthly)||0.91|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Phibro Animal (PAHC) has been gaining from strong volume growth in foreign markets. However, adverse currency movements remain a concern.
Henry Schein (HSIC) expects the acquisition to be neutral to its 2019 earnings per diluted share and accretive thereafter.
Zimmer Biomet (ZBH) has been working to strengthen foothold in emerging markets. However, the company has been facing continued pricing pressure.
The latest nod from Medicare Coverage for Myriad's (MYGN) myPath Melanoma test is likely to boost top-line results in the near term.
Align Technology (ALGN) will be integrating Digital Smile Design's methodology in functional and aesthetic dentistry with its end-to-end digital workflow covering iTero scanners and Invisalign system.
Receipt of the CE Mark followed by a limited launch of the WATCHMAN FLX device in Europe is likely to drive top-line contributions from Boston Scientific's (BSX) IC suite.
Hologic (HOLX) looks stronger than Varian Medical (VAR) when it comes to current-year earnings projections as well as fundamentals.
Hologic Inc NASDAQ/NGS:HOLXView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for HOLX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative but appears to be improving. Over the last one-month, outflows of investor capital in ETFs holding HOLX totaled $3.39 billion. However, outflows appear to be slowing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
QIAGEN (QGEN) believes that the partnership will aid in improvising the automation of pre-analytic manual steps, leading to its QuantiFERON-TB Gold Plus test.
DexCom (DXCM) looks stronger than Hologic (HOLX) when it comes to current-year earnings and revenue projections as well as fundamentals.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company that is really flourishing, you canRead More...
Moody's Investors Service ("Moody's") changed the outlook on Hologic, Inc.'s (Hologic) ratings to positive from stable, while affirming its Ba2 Corporate Family Rating (CFR) and individual debt ratings. Moody's also affirmed Hologic's Speculative Grade Liquidity Rating at SGL-1.
Richard Blum, the head of private-equity firm Blum Capital, also bought Synopsys stock and sold Hologic stock in January.
Hologic (HOLX) gains from solid double-digit constant currency growth in core businesses like U.S. Breast Health, International and Global Molecular Diagnostics.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 30) Varian Medical Systems, Inc. (NYSE: VAR ) EXACT Sciences ...
Hologic (HOLX) delivered earnings and revenue surprises of 1.75% and 1.51%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
MARLBOROUGH, Mass. (AP) _ Hologic Inc. (HOLX) on Wednesday reported fiscal first-quarter net income of $98.6 million. The Marlborough, Massachusetts-based company said it had profit of 36 cents per share. For the current quarter ending in April, Hologic expects its per-share earnings to range from 55 cents to 57 cents.